P. LoRusso

415 total citations
38 papers, 328 citations indexed

About

P. LoRusso is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, P. LoRusso has authored 38 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 18 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in P. LoRusso's work include Cancer Genomics and Diagnostics (8 papers), Cancer Treatment and Pharmacology (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). P. LoRusso is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Cancer Treatment and Pharmacology (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). P. LoRusso collaborates with scholars based in United States, Japan and France. P. LoRusso's co-authors include Geoffrey I. Shapiro, Elisabeth I. Heath, J. R. Infante, Raghu Venkatramanamoorthy, Howard A. Burris, Shirish M. Gadgeel, Lance K. Heilbrun, Andrew Shields, Manuel Valdivieso and Leena Gandhi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

P. LoRusso

37 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. LoRusso United States	12	229	143	84	43	38	38	328
Woody Han United States	6	188 0.8×	141 1.0×	77 0.9×	52 1.2×	28 0.7×	8	345
Rik de Wijn Netherlands	9	182 0.8×	113 0.8×	58 0.7×	52 1.2×	25 0.7×	21	322
Cath Eberlein United Kingdom	8	160 0.7×	81 0.6×	55 0.7×	42 1.0×	23 0.6×	17	262
S. Ogawa Japan	5	164 0.7×	141 1.0×	97 1.2×	77 1.8×	36 0.9×	5	303
Anni Laine Finland	5	274 1.2×	178 1.2×	55 0.7×	60 1.4×	21 0.6×	6	392
Megan M. Starr United States	4	181 0.8×	180 1.3×	98 1.2×	45 1.0×	17 0.4×	4	335
Hao Mo China	13	226 1.0×	135 0.9×	86 1.0×	85 2.0×	25 0.7×	32	436
Mette Villingshøj Denmark	11	231 1.0×	157 1.1×	66 0.8×	86 2.0×	106 2.8×	14	405
Tim Perera Italy	5	160 0.7×	145 1.0×	77 0.9×	32 0.7×	18 0.5×	8	298
Özge Alper United States	9	200 0.9×	180 1.3×	38 0.5×	41 1.0×	27 0.7×	12	365

Countries citing papers authored by P. LoRusso

Since Specialization

Citations

This map shows the geographic impact of P. LoRusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. LoRusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. LoRusso more than expected).

Fields of papers citing papers by P. LoRusso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. LoRusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. LoRusso. The network helps show where P. LoRusso may publish in the future.

Co-authorship network of co-authors of P. LoRusso

This figure shows the co-authorship network connecting the top 25 collaborators of P. LoRusso. A scholar is included among the top collaborators of P. LoRusso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. LoRusso. P. LoRusso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Medina, Jamie E., Evanthia T. Roussos Torres, Vilmos Adleff, et al.. (2022). 1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes. Annals of Oncology. 33. S1306–S1307. 1 indexed citations

Yamamoto, Noboru, et al.. (2022). 452O A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours. Annals of Oncology. 33. S743–S743. 2 indexed citations

Yee, Douglas, Aleix Prat, Marie‐Paule Sablin, et al.. (2017). A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/- endocrine therapy), or non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. x25–x25. 2 indexed citations

Messersmith, Wells A., P. LoRusso, James M. Cleary, et al.. (2012). 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies. European Journal of Cancer. 48. 180–180. 7 indexed citations

Keedy, Vicki L., Pasi A. Jänne, Lorrin Yee, et al.. (2011). A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3026–3026. 7 indexed citations

Sausville, Edward A., P. LoRusso, Michael A. Carducci, et al.. (2011). Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3058–3058. 12 indexed citations

Messersmith, Wells A., P. LoRusso, Arvind Dasari, et al.. (2011). A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3100–3100. 4 indexed citations

Cervantes, Andrés, María Alsina, Josep Tabernero, et al.. (2011). Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology. 29(15_suppl). 3025–3025. 44 indexed citations

Darbonne, Walter C., Xing Du, Punita Dhawan, et al.. (2011). Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients.. Journal of Clinical Oncology. 29(15_suppl). e13598–e13598. 10 indexed citations

10.

Moldovan, Cristian, Jean‐Charles Soria, P. LoRusso, et al.. (2010). A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3070–3070. 18 indexed citations

11.

Menefee, Michael E., P. LoRusso, Jennifer McDevitt, et al.. (2010). 3LB MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors. European Journal of Cancer Supplements. 8(7). 3–4. 1 indexed citations

12.

Ratain, Mark J., Linda Janisch, Janice Smith, et al.. (2010). 388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors. European Journal of Cancer Supplements. 8(7). 123–123. 2 indexed citations

13.

Egorin, Merrill J., Shivaani Kummar, John Sarantopoulos, et al.. (2010). Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057).. Journal of Clinical Oncology. 28(15_suppl). 2545–2545. 1 indexed citations

14.

Gollob, Jared, J. R. Infante, Geoffrey I. Shapiro, et al.. (2010). Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology. 28(15_suppl). 3042–3042. 7 indexed citations

15.

LoRusso, P., Ian E. Krop, H.A. Burris, et al.. (2010). Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.. Journal of Clinical Oncology. 28(15_suppl). 1016–1016. 12 indexed citations

16.

Mita, Monica, Lorrin Yee, K. Papadopoulos, et al.. (2008). 42 POSTER NPI-2358 (a novel vascular disrupting agent) Phase 1 dose escalation trial with an RP2D cohort. European Journal of Cancer Supplements. 6(12). 17–17. 1 indexed citations

17.

Hurwitz, H., P. LoRusso, Geoffrey I. Shapiro, et al.. (2008). 429 POSTER Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors. European Journal of Cancer Supplements. 6(12). 135–135. 2 indexed citations

18.

Markman, B., P. LoRusso, Akash Patnaik, et al.. (2008). 216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. European Journal of Cancer Supplements. 6(12). 68–69. 10 indexed citations

19.

Sausville, E. A., P. LoRusso, Mary Quinn, et al.. (2007). A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2577–2577. 14 indexed citations

20.

Beeram, M., Chris H. Takimoto, Masayuki Kimura, et al.. (2004). Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. Journal of Clinical Oncology. 22(14_suppl). 2028–2028. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact